Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 651-kidney-transplant-with-hemodialysis-without-mcc
    Ask Trek AI about this page

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    DRG 651 applies to inpatient stays for kidney transplant recipients who receive hemodialysis during the admission without a Major Complication or Comorbidity, defining the clinical scope and expected resource use for payment. It matters for inpatient reimbursement because Medicare payment uses Diagnosis-Related Group assignment to set the prospective bundled payment for these combined surgical and dialysis services.

    Customize your policy alerts

    Sign up for drg 651 policy alerts

    Get alerted when payer policies referencing 651 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 651 Overview

    DRG 651 covers hospital stays for patients undergoing kidney transplant who receive hemodialysis during the same inpatient episode without a Major Complication or Comorbidity. This Diagnosis-Related Group captures the resource use associated with transplantation plus perioperative dialysis support and affects Medicare payment by grouping charges into a single prospective payment category. Accurate coding of diagnoses and procedures determines assignment to this DRG and therefore impacts reimbursement. The classification distinguishes higher-acuity cases that include Major Complication or Comorbidity from this category.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative immunosuppression optimization studies: trials examining different induction and maintenance immunosuppressive regimens around the time of kidney transplant in recipients who require perioperative hemodialysis. These studies focus on immediate graft function, rates of delayed graft function, rejection incidence, and early infectious complications among adult transplant recipients with preexisting dialysis dependence. Results inform clinicians about balancing rejection prevention and infection risk in the critical early post-transplant period and help payers anticipate costs related to graft dysfunction, readmission, and medication utilization.
    • Comparative effectiveness research on intraoperative and perioperative dialysis strategies: randomized or observational studies comparing approaches such as intraoperative hemodialysis versus scheduled immediate post-op dialysis, or variations in dialysis prescription (ultrafiltration goals, anticoagulation) in transplant recipients who continue to require hemodialysis. The studied population includes patients undergoing kidney transplant who remain dialysis-dependent at or shortly after surgery, with outcomes including fluid balance, electrolyte stability, hemodynamic events, graft perfusion metrics, and short-term renal recovery. Findings are relevant for surgical teams and hospital administrators because optimized dialysis timing and technique can reduce intra- and post-operative complications, shorten ICU/hospital stays, and impact resource utilization and reimbursement under this DRG.
    • Post-discharge outcomes and care coordination studies: observational cohorts and interventional trials testing protocols for early post-discharge management (e.g., intensive outpatient dialysis follow-up, structured transplant clinic pathways, telemonitoring) aimed at patients who required perioperative hemodialysis. These studies evaluate readmission rates, graft survival at 30–90 days, infection and access-related complications, and adherence to immunosuppression in the early recovery phase. Evidence supports payers and providers in designing post-discharge care models that reduce costly readmissions and improve short-term graft outcomes for this high-risk DRG population.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.